Biotech analyst in response to a question today on Street Insight: REGN: Up With the Sector, but Risks Remain 06/02/03 02:53 PM EDT Reader: Can Sally Yanchus comment on Regeneron (REGN:Nasdaq) now trading at $15.24? This seems to be one biotech that is being carried upward without any real substance behind the move. -- Andrew Altchek
Sally Yanchus: REGN has rebounded because of the euphoria for biotech and also because the weight loss drug Axokine showed some limited benefits in some patient sub-populations. But I don't think that the data was good enough to characterize Axokine as a "success" because at best, if it does get approved, its market potential will be limited.
I would not be a buyer of REGN here.
Sally Yanchus is an analyst and consultant for health care clients. From 1997 through 2001, Yanchus worked as a buy-side analyst covering biotech and pharmaceuticals, first at Zurich Scudder Investments and most recently at The Galleon Group. For eight years before joining the buy side, Yanchus was a sell-side analyst covering biotech, pharmaceuticals and medical devices at Smith Barney, Morgan Stanley, Lehman Bros. and CIBC (now Oppenheimer). She holds a master's in business administration at Columbia University business school and holds a summa cum laude bachelor's from Wellesley College.